BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $0 versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.